NASDAQ:ANL Adlai Nortye (ANL) Stock Price, News & Analysis $1.46 +0.03 (+1.75%) As of 02:24 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock About Adlai Nortye Stock (NASDAQ:ANL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Adlai Nortye alerts:Sign Up Key Stats Today's Range$1.43▼$1.4750-Day Range$1.40▼$1.9952-Week Range$1.10▼$3.89Volume2,897 shsAverage Volume11,558 shsMarket Capitalization$53.69 millionP/E RatioN/ADividend YieldN/APrice Target$9.00Consensus RatingHold Company Overview Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands. Read More Adlai Nortye Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks35th Percentile Overall ScoreANL MarketRank™: Adlai Nortye scored higher than 35% of companies evaluated by MarketBeat, and ranked 659th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingHold Consensus RatingAdlai Nortye has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAdlai Nortye has only been the subject of 1 research reports in the past 90 days.Read more about Adlai Nortye's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Adlai Nortye are expected to decrease in the coming year, from ($0.88) to ($0.92) per share.Price to Book Value per Share RatioAdlai Nortye has a P/B Ratio of 2.11. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Adlai Nortye's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.01% of the outstanding shares of Adlai Nortye have been sold short.Short Interest Ratio / Days to CoverAdlai Nortye has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Adlai Nortye has recently decreased by 15.15%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAdlai Nortye does not currently pay a dividend.Dividend GrowthAdlai Nortye does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.01% of the outstanding shares of Adlai Nortye have been sold short.Short Interest Ratio / Days to CoverAdlai Nortye has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Adlai Nortye has recently decreased by 15.15%, indicating that investor sentiment is improving significantly. News and Social MediaN/ANews SentimentN/A Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Adlai Nortye insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 35.21% of the stock of Adlai Nortye is held by institutions.Read more about Adlai Nortye's insider trading history. Receive ANL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adlai Nortye and its competitors with MarketBeat's FREE daily newsletter. Email Address ANL Stock News HeadlinesAdlai Nortye Ltd. American Depositary Shares (ANL) - NasdaqJuly 14, 2025 | nasdaq.comHC Wainwright & Co. Downgrades Adlai Nortye - Depositary Receipt () (ANL)June 3, 2025 | msn.comYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…August 1 at 2:00 AM | Crypto 101 Media (Ad)ANL Adlai Nortye Ltd.February 9, 2025 | seekingalpha.comAdlai Nortye And 2 Other Penny Stocks On US Exchanges To WatchFebruary 4, 2025 | finance.yahoo.comAdlai Nortye Ltd. (ANL)January 25, 2025 | ca.finance.yahoo.comAdlai Nortye Announces CFO Transition with Interim AppointmentJanuary 1, 2025 | markets.businessinsider.comWhy Adlai Nortye Ltd. (ANL) Is Among the Chinese Penny Stocks to Buy According to Analysts?December 18, 2024 | msn.comSee More Headlines ANL Stock Analysis - Frequently Asked Questions How have ANL shares performed this year? Adlai Nortye's stock was trading at $2.69 at the beginning of 2025. Since then, ANL shares have decreased by 45.9% and is now trading at $1.4550. When did Adlai Nortye IPO? Adlai Nortye (ANL) raised $58 million in an initial public offering on Friday, September 29th 2023. The company issued 2,500,000 shares at a price of $23.00 per share. How do I buy shares of Adlai Nortye? Shares of ANL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Adlai Nortye own? Based on aggregate information from My MarketBeat watchlists, some other companies that Adlai Nortye investors own include PayPal (PYPL), Avino Silver & Gold Mines (ASM), nCino (NCNO), Construction Partners (ROAD), Taiwan Semiconductor Manufacturing (TSM), XPeng (XPEV) and Cogent Communications (CCOI). Company Calendar Today8/01/2025Next Earnings (Estimated)8/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ANL Previous SymbolNASDAQ:ANL CIK1944552 Webwww.adlainortye.com Phone848-230-7430FaxN/AEmployees127Year FoundedN/APrice Target and Rating Average Price Target for Adlai Nortye$9.00 High Price Target$9.00 Low Price Target$9.00 Potential Upside/Downside+518.6%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.02 Current Ratio1.41 Quick Ratio1.41 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.69 per share Price / Book2.11Miscellaneous Outstanding Shares36,900,000Free FloatN/AMarket Cap$53.69 million OptionableNot Optionable Beta-0.95 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:ANL) was last updated on 8/1/2025 by MarketBeat.com Staff From Our PartnersWall Street Hates This Gold IRA Strategy—Here’s WhyWhat if I told you there's a legal way to own real physical gold and silver—and keep your gains tax-free? N...Advantage Gold | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredI’d rather trade news like this than gamble on hypeReal traders are watching Nvidia’s next move—after U.S. approval to resume chip sales to China. This reversal ...Timothy Sykes | SponsoredThis New Rule Could Change EverythingA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!99.8% voted YES on this crypto partnership Kraken—one of the world's biggest crypto exchanges—just picked O...Crypto 101 Media | SponsoredIf you saw this, you'd be scared tooMarkets may look strong—but one veteran analyst warns we’re nearing a financial breaking point. After 40+ y...InvestorPlace | SponsoredWhy “The Prophet” Is Betting Big on This $10 StockAmerica's Biggest Land Grab Is Not Where You Think While the media focuses on coastal cities and farmland.....Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adlai Nortye Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Adlai Nortye With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.